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Gag proteins direct the process of retroviral particle
assembly and form the major protein constituents of
the viral core. The matrix region of the HIV-1 Gag poly-
protein plays a critical role in the transport of Gag to
the plasma membrane assembly site. Recent evi-
dence indicates that Gag trafficking to late endoso-
mal compartments, including multivesicular bodies,
occurs prior to viral particle budding from the plasma
membrane. Here we demonstrate that the matrix re-
gion of HIV-1 Gag interacts directly with the  subunit
of the AP-3 complex, and that this interaction plays
an important functional role in particle assembly. Dis-
ruption of this interaction eliminated Gag trafficking
to multivesicular bodies and diminished HIV particle
formation. These studies illuminate an early step in
retroviral particle assembly and provide evidence that
the trafficking of Gag to late endosomes is part of a
productive particle assembly pathway.
Introduction
The process of retroviral particle assembly is directed
by the Gag polyprotein (Freed, 1998; Wills and Craven,
1991). Gag proteins expressed in the absence of any
other viral components are capable of eliciting the for-
mation of virus-like particles (pseudovirions) of the au-
thentic size, density, and morphology of the infectious
virion. HIV Gag proteins are cleaved by the viral prote-
ase during the budding process into four structural pro-
teins that perform unique functions in the mature virion
(MA, CA, NC, and p6, listed from amino to carboxyl ter-
minus). During assembly, the uncleaved Gag polypro-
tein interacts with the viral RNA and the envelope gly-
coprotein complex (Env) to coordinate the production
of infectious virions. Gag interacts with a number of
cellular factors that play an essential role in particle
budding as Gag makes its way to the plasma mem-
brane assembly site (Luban, 2001; Martin-Serrano et
al., 2003; Strack et al., 2003; von Schwedler et al.,
2003).*Correspondence: paul.spearman@vanderbilt.eduHIV budding occurs predominantly at the plasma
membrane in T lymphocytes and most transformed epi-
thelial cell lines (Freed, 1998; Ono and Freed, 2004;
Spearman et al., 1994). Pr55Gag is synthesized on free
cytosolic ribosomes and traffics to the plasma mem-
brane assembly site by pathways that are not yet com-
pletely defined. The discovery that Gag interacts with
TSG101 and other components of the vacuolar protein
sorting (Vps) pathway has led to new insights into the
route taken by Gag in the cell (Garrus et al., 2001; Ver-
Plank et al., 2001). TSG101 is a component of the
ESCRT-I complex and plays a key role in the biogenesis
of multivesicular bodies (MVBs) (Babst et al., 2000;
Katzmann et al., 2001). Gag binds directly to the UEV
domain of TSG101 through a tetrapeptide (PTAP) do-
main located in the carboxyl-terminal p6 domain. In this
manner, Gag acts as an Hrs homolog and diverts
TSG101 and other ESCRT components from their role
in MVB formation to assist in the late steps of particle
assembly (Pornillos et al., 2003).
In some cells, HIV particle budding occurs directly
into the MVB rather than from the plasma membrane.
This phenomenon is prominent in primary macro-
phages, where it appears to be the major productive
pathway involved in particle formation and release
(Nguyen et al., 2003; Ono and Freed, 2004; Raposo et
al., 2002). Some investigators have postulated that
budding into late endosomes is important in most cell
types and have suggested that Gag acts as a cargo
molecule for normal cellular exocytic machinery (the
“Trojan exosome” hypothesis) (Gould et al., 2003; Ngu-
yen et al., 2003). While the role of HIV budding into en-
dosomes in most relevant cell types such as primary T
cells is debated, it is clear that Gag and MVB markers
colocalize in a wide variety of cells (Nydegger et al.,
2003; Sherer et al., 2003). It is likely that specific cellular
trafficking machinery is responsible for bringing Gag to
the MVB.
In order to better understand the process of HIV par-
ticle assembly, it is necessary to identify the specific
cellular factors responsible for the trafficking of Gag
within the cell. Here we report that Gag interacts di-
rectly with the δ subunit of the AP-3 complex, in an
interaction mediated by the amino-terminal α-helical
segment of matrix (MA). Disruption of this interaction
prevents Gag from reaching the MVB compartment and
inhibits particle formation. Our observations highlight
an early step in the HIV assembly pathway that takes
Gag to the late endosome/MVB compartment and sug-
gest that the trafficking of Gag to this compartment is
part of the normal productive pathway of HIV-1 as-
sembly.
Results
HIV-1 Gag Binds Specifically to the  Subunit
of the AP-3 Complex
We performed a yeast two-hybrid screen of a HeLa
cDNA library using full-length HIV-1 Gag as bait to iden-
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664tify Gag binding partners. Our screen identified TSG101
and cyclophilin B, two previously identified Gag-inter-
acting proteins (Franke et al., 1994; Garrus et al., 2001;
VerPlank et al., 2001), as well as new candidate Gag
binding partners. One candidate chosen for further
evaluation was the δ subunit of AP-3. Our screen iden-
tified a fragment representing amino acids 554–844 of
the δ subunit, which overlaps the hinge region and the
C-terminal portion of the head of AP-3 δ. The interac-
tion was confirmed in yeast by measuring β-galactosi-
dase levels in liquid culture assays (Figure 1B). Addi-
tional truncation constructs narrowed the Gag binding
region on AP-3 δ to amino acids 641–742, located en-
tirely within the hinge region (data not shown).
Directed yeast two-hybrid experiments were used to
map the AP-3 δ subunit binding site within Gag. Dele-
tion of MA from Gag eliminated specific binding, while
C-terminal truncations of Gag that retained an intact
MA region maintained the binding characteristics of the
full-length molecule (Figure 1B). We next examined in-
dividual fragments representing each major cleavage
product of Gag (MA, CA, NC, p6); only the MA fragment
bound at levels significantly above background (Figure
1B). A set of nested deletions within MA were then eval-
uated (Yu et al., 1992) and revealed loss of interaction
with deletions surrounding the N-terminal α helix of MA
(MAD-1 and MAD-2, Figure 1C). To confirm the impor-
tance of the N-terminal α helix (H1), a fragment ex-
pressing the N terminus of MA up to residue 19 demon-
strated interaction in yeast (pGBKT7-H1), while a
specific deletion of this same fragment failed to bind to
the AP-3 δ subunit (Figure 1D). An N-terminal fragment
of MA truncated after residue 12 failed to interact (data
not shown). We conclude that the N-terminal α helix of
MA, a region previously implicated in Gag trafficking
(Ono et al., 2000), is the binding site for the AP-3 δ
subunit.
We next sought to verify the Gag-AP-3 δ interaction
using recombinant Gag protein produced in E. coli.
Gag-GST fusion constructs were prepared and eval-
uated for binding to the AP-3 δ subunit from 293T cell
lysates. No interaction was seen with GST alone or with
GST fusions with CA, NC, or p6 (Figure 2A). Cellular
AP-3 δ bound to full-length GST-Gag, Gag lacking p6
(GST-MACANC), Gag lacking NC and p6 (GST-MACA),
and with GST-MA alone (Figure 2A). A purified protein F
fragment representing the interacting domain of the t
AP-3 δ subunit (amino acids 554–844) bound directly to (
oGST-MA and not to fusion proteins representing other
imajor regions of Gag (Figure 2C, asterisk). These re-
tsults indicate that there is a direct and specific protein-
(
protein interaction between the MA region of Gag and G
the AP-3 δ subunit. t
r
iGag Interacts with the AP-3  Subunit
ain Mammalian Cells
r
An N-terminal fragment of the AP-3 δ subunit bearing a
an HA epitope tag (HA-AP-3D-5#) was expressed to- (
gether with a full-length Gag molecule bearing a C-ter- d
tminal myc epitope tag (Gag-myc) in 293T cells. Immu-
(noprecipitation of Gag demonstrated interaction with
HA-AP-3D-5# as detected by anti-HA immunoblotting
(Figure 3A). HA-tagged TSG-5#, an N-terminal fragmentigure 1. Yeast Two-Hybrid Analysis of the Gag-AP-3 δ Subunit In-
eraction
A) Schematic illustration of AP-3 adaptor complex and position
f relevant fragments. The original interacting fragment (554–844)
solated from a HeLa cDNA library is shown, together with the posi-
ion of the AP-3D-5# and AP-3D-3# fragments.
B) Mapping studies of the AP-3 δ subunit binding domain within
ag. The interactions between different Gal4 DNA-BD fusion pro-
eins (left graph) and Gal4 AD fusion protein bearing the interacting
egion of AP-3 δ were tested for growth and α-galactosidase activ-
ty on solid media (indicated by +) and by liquid β-galactosidase
ssays (right) in replicate experiments. Liquid β-galactosidase data
epresent the mean ± SD from triplicate experiments. The top three
ssays are negative controls.
C) Mapping of the AP-3 δ subunit binding domain within MA. MA
eletion constructs expressed in yeast were assayed for interac-
ion with the AP-3 δ 554–844 fragment as in (B).
D) Fine mapping of the AP-3 δ subunit binding domain within MA.
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665Figure 2. GST Pulldown Analysis of the Gag-AP-3 δ Subunit In-
teraction
(A) HIV-1 MA binds to endogenous AP-3 δ subunit. GST fusion pro-
teins representing the indicated regions of Gag bound to glutathi-
one beads were incubated with cell lysates of 293T cells, followed
by immunoblotting for adaptin δ. The input adaptin δ protein from
the 293T cell lysate is shown on the right.
(B) Coomassie blue staining of fusion proteins used in (A).
(C) The purified interacting fragment (AP-3 δ 554–844) was incu-
bated with bead bound GST-Gag fusion proteins, followed by elu-
tion and analysis by Coomassie blue staining. Purified interacting
fragment is shown in the rightmost lane and is indicated in the GST-
MA lane by an asterisk.of TSG101 that includes the p6 binding region, was co-
precipitated with Gag-myc in this assay as a positive
control. The reciprocal immunoprecipitation was then
performed and again demonstrated the coimmuno-
precipitation of Gag-myc with HA-AP-3D-5# (Figure 3B).
In order to detect the interaction of Gag with endoge-
nous AP-3 in mammalian cells, immunoprecipitation of
Gag-myc was performed using an anti-myc monoclonal
antibody followed by immunoblotting for the AP-3 δ
subunit. Gag-myc precipitated the full-length endoge-
nous AP-3 δ subunit (Figure 3C). In contrast, a particle-
competent Gag-myc construct bearing the v-src myris-
tylation signal and lacking MA failed to precipitate the
AP-3 δ subunit (SrcMAGag-myc, lane 3 of Figure 3C).
To further examine this interaction, full-length proviral
DNA (pNL4-3) was transfected into HeLa cells, then
Gag was immunoprecipitated using an anti-CA mono-
clonal antibody. The endogenous AP-3 δ subunit copre-
cipitated with Gag (Figure 3D). These results demon-
strate that Gag interacts with the AP-3 δ subunit in
mammalian cells when Gag alone is expressed and in
the context of expression of an infectious provirus.An N-Terminal Fragment of the AP-3  Subunit
Acts as a Dominant-Negative Inhibitor
of Particle Assembly
We next performed experiments designed to investi-
gate the biological significance of the Gag-AP-3 in-
teraction. We reasoned that expression of a fragment
of AP-3 δ overlapping the Gag binding domain (AP-3D-
5#) could block the interaction of Gag with the endo-
genous AP-3 complex. To study the effects of this
molecule on particle formation, we expressed AP-3D-
5# together with pNL4-3 in 293T cells and measured
particle release by p24 antigen ELISA. AP-3D-5# ex-
pression inhibited particle assembly/release from 293T
cells in a manner similar to that of a dominant-negative
TSG101 construct (Figure 4A). AP-3D-5# demonstrated
a significant inhibition of particle release by a Gag/pro-
tease expression construct (Figure 4B), eliminating the
possibility that Env or additional viral gene products are
required for AP-3D-5#-mediated inhibition of assembly.
The inhibitory effect of AP-3D-5# was dose dependent
(Figure 4C). Western blotting of cell lysates and of pel-
leted virion particles revealed an AP-3D-5# dose-depen-
dent decrease in released p24 antigen corresponding
to the ELISA results (Figure 4D). We considered the
possibility that the inhibition of particle release seen
upon overexpression of AP-3D-5# was due to cellular
toxicity or enhanced degradation of Pr55Gag. However,
intracellular levels of Pr55Gag and of endogenous AP-3
δ subunit did not decrease substantially at ratios of
pNL4-3 DNA/AP-3D-5# DNA ranging from 1:1 to 1:3
(Figure 4D). The half-life of Pr55Gag in cells expressing
AP-3D-5# was prolonged compared to that observed in
cells lacking AP-3D-5#, reflecting the fact that Pr55Gag
was retained within cells in which the dominant-nega-
tive construct was expressed and indicating that the
effects of AP-3D-5# on particle release were not due to
enhanced degradation of Gag (Figures S1A and S1B
available with this article online). The inhibitory effects
of AP-3D-5# on particle release were not seen upon ex-
pression of a C-terminal fragment of AP-3 δ subunit that
lacked the Gag interaction domain (AP-3D-3#, Figure
4E). Taken together, these data demonstrate that AP-
3D-5# acts as a dominant-negative inhibitor of as-
sembly.
Depletion of the AP-3 Complex Inhibits
HIV Particle Assembly
To further define the role of the AP-3 complex in HIV
particle assembly, we depleted the cellular AP-3 com-
plex from 293T or HeLa cells using siRNA techniques.
To achieve a significant depletion of the AP-3 complex
in 293T cells, we expressed siRNA for both the δ and 
subunits of the complex and transfected 293T cells
with the combined siRNA at two time points. In cells
cotransfected with pNL4-3 following a single treatment
with siRNA, particle release was inhibited by more than
50% as compared with cells receiving control siRNA
(Figure 5A, T1). A second treatment with siRNA resulted
in enhanced depletion of the  and δ subunits, and par-
ticle release was inhibited by more than 80% as com-
pared with transfection of control siRNA (Figure 5A, T2).
The progressive depletion of particle release corre-
sponded to enhanced depletion of endogenous AP-3
Cell
666Figure 3. Coimmunoprecipitation of Gag and
the AP-3 δ Subunit
(A) Coimmunoprecipitation of AP-3D-5# and
HIV-1 Gag. 293T cells were cotransfected
with Gag-myc and either HA-AP-3D-5# or
HA-TSG-5# as a positive control. Proteins
were immunoprecipitated using anti-myc an-
tibodies (second and fourth lanes) or using
only protein G sepharose beads (first and
third lanes). Coprecipitated HA-AP-3D-5# was
detected by immunoblotting with an anti-HA
monoclonal antibody (top panel). Cell lysates
are shown prior to immunoprecipitation as
probed by the anti-HA antibody (middle
panel) or anti-myc antibody (bottom panel).
(B) Reciprocal coimmunoprecipitation of
HIV-1 Gag and AP-3D-5#. Cell lysates were
prepared as in (A), with immunoprecipitation
using anti-HA antibody and detection using
anti-myc monoclonal antibody.
(C) Immunoprecipitation of HIV-1 Gag and
endogenous AP-3 δ subunit. Proteins were
immunoprecipitated from the untransfected
293T cell lysates (input) or transfected ly-
sates using anti-myc polyclonal antisera and
detected by Western blot with anti-adaptin
δ (top panel). Anti-myc Western blot (middle
panel) and anti-adaptin δ Western blot (bot-
tom panel) of the whole-cell lysates are
shown.
(D) Immunoprecipitation of NL4-3 and en-
dogenous AP-3 δ subunit. Gag proteins were
immunoprecipitated from the mock-trans-
fected HeLa cell lysates (lane 1) or pNL4-3
transfected cell lysates (lane 2) using an anti-
capsid monoclonal antibody and immuno-
blotted with anti-adaptin δ (top panel) and
anti-capsid antibodies (middle panel). West-
ern blot with anti-adaptin δ of samples prior
to immunoprecipitation is shown in the bot-
tom panel.components seen in cell lysates, while the AP-1 γ sub- a
bunit was unaffected (Figure 5B). In HeLa cells, a marked
and reproducible inhibition of particle release was dem- e
Aonstrated following siRNA transfection targeting only
the δ subunit (Figure 5C). As an additional control for i
fthe specificity of this effect, we expressed a myristy-
lated Gag molecule in which MA has been deleted t
(SrcMAGag). The release of SrcMAGag was not sig- c
nificantly diminished following siRNA-mediated deple- n
tion of the AP-3 δ subunit in HeLa cells (Figure 5D). c
These results indicate that the Gag-AP-3 δ subunit in- 3
teraction mediates a productive pathway in particle as- d
sembly and suggest that the v-src myristylation signal t
in the context of MA-deleted Gag allows Gag to bypass p
the AP-3 trafficking pathway. C
u
lThe Gag-AP-3 Interaction Is Required for Gag
wTrafficking to MVBs
aThe AP-3 adaptor complex is known to direct the intra-
ccellular trafficking of protein components, such as CD63,
Tof the MVB (Dell’Angelica et al., 1999; Pelchen-Mat-
nthews et al., 2003; Rous et al., 2002). We hypothesized
Ythat the trafficking of Gag to MVBs may similarly be
under the control of AP-3. To test this hypothesis, we pnalyzed by confocal microscopy the subcellular distri-
ution of Gag-CFP and endogenous CD63 in the pres-
nce or absence of the dominant-negative YFP-tagged
P-3D-5# fragment. When analyzed at early time points
n HeLa cells (12–14 hr posttransfection), a significant
raction of Gag-CFP expressed alone was found in in-
racellular, punctate sites (Figure 6A). There was signifi-
ant colocalization seen with Gag-CFP and endoge-
ous CD63 (Figures 6A, 6E, and 6I). In the majority of
ells in which Gag-CFP was coexpressed with YFP-AP-
D-5#, Gag was found in a more diffuse cytoplasmic
istribution (Figures 6P, 6R, and 6U). However, even in
hose cells, expressing YFP-AP-3D-5#, that retained a
unctate pattern of Gag (Figure 6B), colocalization with
D63 was not observed (Figure 6J). This effect was not
nique to the Gag-CFP molecule, as wild-type Gag co-
ocalization with CD63 analyzed by immunostaining
as similar to that seen with Gag-CFP (Figures 6C, 6G,
nd 6K). YFP-AP-3D-5# similarly resulted in a signifi-
ant decrease in Gag-CD63 colocalization (Figure 6L).
he pattern of endogenous CD63 remained predomi-
antly intracellular and punctate in all cells expressing
FP-AP-3D-5# (represented by Figures 6F and 6H). The
ercentage of colocalization of Gag-CFP to CD63 over
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667Figure 4. Dominant-Negative Inhibition of Particle Assembly/
Release by AP-3D-5#
(A) AP-3D-5# effects on NL4-3 particle assembly. 293T cells were
cotransfected with pNL4-3 in a 1:1 mixture with control pcDNA3.1,
TSG-5#, or AP-3D-5# expression vectors. p24 antigen release into
supernatants was measured at 72 hr by antigen-capture ELISA.
Data shown represent mean ± SD from triplicate wells.
(B) AP-3D-5# effects on Gag/pro-mediated particle assembly. 293T
cells were transfected with Gag/pro expression vector in a 1:1 mix-
ture with control pCDNA 3.1, TSG-5#, or AP-3D-5# expression vec-
tors. p24 antigen release into supernatants was measured at 72 hr
by antigen-capture ELISA.
(C) Dose-dependent inhibition of assembly by AP-3D-5#. 293T cells
were cotransfected with NL4-3 expression vector and AP-3D-5# ex-
pression vector at the indicated ratios (pNL4-3/AP-3D-5#). Super-
natant p24 was quantified at 72 hr posttransfection by ELISA.
(D) Western blot analysis of dose-dependent inhibition. Cyto-
plasmic extracts (top panel) and pelleted virus (middle panel) of
samples obtained 72 hr after transfection from the experiment out-
lined in (C) were harvested and analyzed by Western blot using
pooled sera from HIV+ patients. The levels of expressed endoge-We considered the possibility that some of our re-
nous AP-3 δ subunit (AP-3D) and overexpressed AP-3D-5# as de-
tected by anti-adaptin δ Western blot are shown below.
(E) Lack of inhibition on particle assembly by AP-3D-3#. 293T cells
were cotransfected with NL4-3 expression vector and AP-3D-3# ex-
pression vector at the indicated ratios, and p24 output in the super-
natant was analyzed as in (C).time was then calculated using the Metamorph soft-
ware package in cells that did or did not express YFP-
AP-3D-5#. Figure 6M demonstrates that Gag-CFP-
CD63 colocalization increased over time, but that colo-
calization was significantly disrupted by the expression
of AP-3D-5#. Similarly, Gag (without CFP) colocalization
with CD63 was quantitatively diminished by expression
of YFP-AP-3D-5# (Figure 6N). The expression of a YFP-
tagged dominant-negative AP-3 fragment allowed us to
sometimes identify cells that differed dramatically in
expression of this inhibitory molecule within the same
microscopic field. Figures 6O and 6P demonstrate a
pair of cells expressing Gag-CFP, of which only the bot-
tom cell expresses the inhibitor. Colocalization of en-
dogenous CD63 and Gag-CFP is observed in the upper
cell (Figure 6P, an overlay of Gag-CFP and CD63
images), while no colocalization is apparent in the cell
expressing the inhibitor (Figure 6P, lower cell).
We next asked if Gag was prevented from trafficking
to the plasma membrane in cells expressing AP-3D-5#.
To address this, cells were transfected with Gag-CFP
and YFP-AP-3D-5# and examined for Gag-CFP distri-
bution at a later time point (20 hr posttransfection). Fig-
ures 6Q and 6R present a pair of cells with differential
expression of YFP-AP-3D-5# examined at 20 hr post-
transfection. Note that the cell expressing the domi-
nant-negative inhibitor (the lower cell) exhibits a more
diffuse, cytoplasmic pattern of Gag than the upper cell,
which retains a punctate pattern. This is representative
of the predominant pattern seen by confocal micro-
scopy at this time point. In order to apply quantitative
methods to this observation, we first identified three
patterns of Gag-CFP seen within the population of
cells. Figure 6S represents the plasma membrane dis-
tribution pattern, Figure 6T represents the intracellular
punctate distribution pattern, and Figure 6U represents
the intracellular diffuse pattern. We then enumerated
each pattern from images taken of cells expressing
Gag-CFP alone or in the presence of YFP-AP-3D-5#.
Figure 6V demonstrates that the punctate and plasma
membrane patterns of Gag were prominent in cells ex-
pressing Gag-CFP alone, while the diffuse pattern was
the dominant phenotype in cells expressing the domi-
nant-negative inhibitor. We noted that a subset of cells
exhibited a plasma membrane distribution of Gag even
in the presence of the inhibitor, suggesting either in-
complete inhibition of the AP-3 interaction in these
cells or that alternative pathways exist that can lead to
Gag-plasma membrane association. Overall, the major
conclusions from our imaging data were (1) disruption
of the Gag-AP-3 interaction eliminates Gag-CD63 colo-
calization and (2) AP-3D-5# disrupts both punctate in-
tracellular and plasma membrane patterns of Gag and




































Figure 5. Inhibition of HIV-1 Particle Assembly by siRNA-Mediated h
Depletion of the AP-3 Complex s
(A) 293T cells were transfected with a pool of anti-AP-3 δ and anti- p
AP-3  siRNA duplexes or with control RNA duplexes. A second i
transfection with siRNA and pNL4-3 was performed 24 hr later, and e
supernatants were harvested 24 hr following the second transfec-
ttion (T1). In a parallel experiment, two siRNA transfections were
pperformed 24 hr apart, followed 24 hr later by the siRNA/pNL4-3
wcotransfection, and harvesting after an additional 24 hr (T2). Con-
trol siRNA transfections were performed separately for each of b
these experimental arms, and the results are presented as percent
of the p24 antigen release as compared with the corresponding d
control arm. Data shown represent mean ± SD from triplicate ex-
Mperiments.
A(B) Western blot demonstrating enhanced depletion of AP-3 δ and
i subunits at T2 of the same experiment depicted in (A), and the
corresponding decrease in released viral particles as indicated by p
p24. Control Western blot of cell lysates demonstrating AP-1 γ sub- m
unit is shown. (
(C) Depletion of AP-3 δ in HeLa cells inhibits particle assembly.
eCells were transfected with a pool of siRNA directed against AP-3
fδ or control RNA duplexes and 24 hr later were cotransfected with
sthe same RNA pool and pNL4-3. Top panel demonstrates depletion
of AP-3 δ subunit. Bottom graph indicates p24 antigen release fol- w
lowing control (left) or following specific depletion of the AP-3 δ m
subunit. l
(D) Resistance of SrcMAGag to inhibition by depletion of AP-3.
pHeLa cells were treated with inhibitory RNA or control RNA exactly
7as in (C) except that SrcMAGag was cotransfected instead of
2pNL4-3. Top panel indicates δ subunit depletion, bottom graph de-
picts particle release. m
bults could reflect an effect of AP-3D-5# on late endo-
omal trafficking in general. However, AP-3D-5# expres-
ion did not alter the plasma membrane expression of
D63 as quantified by flow cytometry, and the lyso-
omal enzyme cathepsin D was processed in the lyso-
ome at normal levels (Figure S2), indicating that late
ndosomal trafficking remained intact in the presence
f the dominant-negative inhibitor.
ominant-Negative Inhibition of the Gag-AP-3
nteraction Creates an Assembly Block
istinct from that of TSG-5
e used transmission electron microscopy to define
he stage of the block to assembly introduced by AP-
D-5# and compared it with TSG-5#. Normal particle
udding was readily observed in 293T cells expressing
he NL4-3 provirus in control experiments (Figures 7A
nd 7B). Cells transfected with pNL4-3 and TSG-5#
emonstrated prominent particle buds that were ar-
ested at the plasma membrane, as previously reported
or a late budding defect (Figure 7C). In cells trans-
ected with pNL4-3 and AP-3D-5# at a 1:1 ratio, in con-
rast, very few budding particles were observed (il-
ustrated by the cell shown in Figure 7D). To provide
ome quantitation of this observation, we examined
00 consecutive cells prepared for thin-section electron
icroscopy expressing NL4-3 alone, NL4-3 with TSG-5#,
r NL4-3 with AP-3D-5#. Of 100 consecutive cells
ounted, we observed 10 cells with obvious particle
udding in pNL4-3-transfected preparations, 12 in cells
xpressing NL4-3 and TSG-5# at a 1:1 ratio, and 0 cells
emonstrating particle budding from preparations ex-
ressing NL4-3 and AP-3D-5#. We were able to find rare
ells demonstrating particle budding in cells express-
ng NL4-3 and AP-3D-5# only after examining several
undred additional fields of cells. Particle budding was
imilarly extremely rare in cells in which the AP-3 com-
lex was depleted using siRNA (data not shown). We
nterpret the paucity of observed particle budding
vents to mean that the block to particle assembly in-
roduced by AP-3D-5# occurs predominantly at a step
receding particle budding. This would be consistent
ith the predominance of the diffuse cytoplasmic distri-
ution of Gag seen by fluorescence microscopy.
We next utilized a 293 cell clone in which Gag is in-
ucibly expressed to examine particle assembly in
VBs. We transfected these cells with YFP-tagged
P-3D-5# then sorted cells for YFP expression prior to
nduction of Gag expression. At 24 hr postinduction,
articles were readily observed at both the plasma
embrane and at intracellular sites in the control cells
Figures 7E and 7F), while the great majority of cells
xpressing YFP-AP-3D-5# demonstrated no particle
ormation at either location (Figure 7I). The intracellular
ites of budding detected in the absence of AP-3D-5#
ere MVBs, as revealed by immunogold labeling electron
icroscopy for CD63 (15 nm beads, Figure 7G). Double
abeling for CD63 and Gag revealed that particles were
resent in the CD63-positive endosomes (inset, Figure
G and 6 nm beads, Figure 7H). We next evaluated the
93 cells in which AP-3D-5# was expressed to deter-
ine if MVBs were present in these cells in equal num-
ers. Morphologically, MVBs were easily identified in
AP-3 and HIV-1 Gag Trafficking
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HeLa cells were transfected with Gag-CFP and empty control plasmid, Gag-CFP and YFP-AP-3-5#, or with Gag (no CFP tag) with and without
YFP-AP-3-5#. Cells were fixed at early (12–14 hr) or late (20 hr, panels Q–V) time points posttransfection and immunostained for Gag and
CD63. Gag-CFP and Gag are shown in green, CD63 in red, and colocalized pixels in yellow. Size bars represent 10 microns.
(A–L) AP-3D-5# inhibits Gag-CD63 colocalization. At early time points, Gag is seen predominantly at intracellular sites (A) and colocalizes with
CD63 (E and overlay, I). In the presence of YFP-AP-3D-5#, even those cells demonstrating punctate Gag-CFP (B) do not demonstrate colocali-
zation with CD63 (F and overlay, J). Similarly, Gag was detected by immunostaining in a pattern that colocalized extensively with CD63 (C, G,
and overlay, K). YFP-AP-3D-5# expression inhibited colocalization (D, H, and overlay, L).
(M) Quantitation of Gag-CFP/CD63 colocalization over time. The percentage of Gag-CFP colocalizing with CD63 was quantified using the
MetaMorph software application for 25 evaluable cells in the Gag-CFP alone arm and 25 cells in the Gag-CFP + YFP-AP-3D-5# arm for each
time point. Error bars = SEM; p values were derived by paired t test.
(N) Quantitation of Gag/CD63 colocalization. Data were collected as in (M), from cells immunostained for Gag and CD63.
(O) YFP image of a pair of cells expressing Gag-CFP and YFP-AP-3D-5#.
(P) Gag-CFP (green) + CD63 (red) image of same pair of cells depicted in (O).
(Q) YFP image of a pair of cells expressing Gag-CFP and YFP-AP-3D-5#.
(R) CFP image of the same pair of cells as (Q).
(S) Plasma membrane pattern of Gag-CFP.
(T) Intracellular punctate distribution pattern of Gag-CFP.
(U) Intracellular diffuse distribution pattern of Gag-CFP.
(V) Quantitation of the three patterns of Gag-CFP distribution at 20 hr posttransfection for Gag-CFP or Gag-CFP + YFP-AP-3D-5# arms. PM =
plasma membrane pattern. Twenty-six cells were counted in the Gag-CFP alone arm, and thiry-two expressing Gag-CFP with YFP-AP-3D-5#.
Cell
670Figure 7. Electron Microscopic Analysis of
Particle Assembly Inhibition by AP-3D-5#
(A and B) 293T cells transfected with NL4-3
DNA alone.
(C) 293T cells expressing NL4-3 and TSG-5#.
(D) Lack of particles seen in 293T cells ex-
pressing NL4-3 and AP-3D-5#.
(E and F) Plasma membrane and intracellular
particle formation from 293 cell clone ex-
pressing inducible Gag and Env.
(G) MVB from 293 cell clone demonstrating
staining with 15 nm gold beads representing
CD63 immunostaining. Six nanomolar beads
used for Gag immunolabeling are difficult to
appreciate at this magnification.
(H) Magnified view from region indicated in
(G) by square. Six nanomolar beads indicate
anti-p17 immunogold staining of particles in
MVB (arrows); two larger (15 nm) beads are
also apparent in this field.
(I) Lack of particle formation in 293 cell clone
expressing Gag and Env following expres-
sion of YFP-AP-3D-5#.
(J) Transmission electron micrograph of MVB
in 293 cell expressing Gag, Env, and YFP-
AP-3D-5#.
(K) Immunolabeling of MVB in 293 cell ex-
pressing Gag, Env, and YFP-AP-3D-5#. Fif-
teen nanomolar gold beads represent anti-
CD63 immunolabeling.
(L) Intracellular particle formation upon
coexpression of NL4-3 bearing a large dele-
tion in MA and YFP-AP-3D-5# in Cos-7 cells.
Double-label immunogold analysis in (G), (H),
and (K) was performed using a monoclonal
anti-CD63 antibody together with anti-
mouse IgG conjugated to 15 nm gold beads
and by rabbit anti-p17 polyclonal sera
marked by anti-rabbit IgG conjugated to 6
nm gold beads. Magnification is 61,600× (A
and B), 17,500 (C), 8800 (D), 13,500 (E),
30,000 (F and G), 116,000 (H), 10,800 (I),
20,000 (J), 24,800 (K), and 34,000 (L). Scale
bars represent 100 nm.these cells (Figure 7J), and CD63 immunostaining 3
dproved that these structures were indeed MVBs (Figure
7K, 15 nm beads). The number of CD63-positive endo- t
bsomes present in serial sections from cells expressing
YFP-AP-3D-5# or control YFP was not significantly dif-
ferent (30 cell sections counted for each, average of 2.4 D
MVBs for YFP and 2.2 MVBs for YFP-AP-3D-5#-treated
cells). Thus, in this cell type, AP-3D-5# blocked particle O
tformation at the plasma membrane and at intracellular
sites but did not disrupt the formation of MVBs. We m
rnoted that at late time points postinduction, the high
level of Gag expression was able to overcome the ef- f
tfect of AP-3D-5#, and both intracellular and plasma
membrane particle assembly could be restored in these n
Acells (data not shown). We conclude that AP-3D-5#
blocked trafficking of Gag to MVBs, as revealed by im- o
tmunofluorescence, and that particle formation at both
intracellular and plasma membrane sites was inhibited c
dby blocking this pathway. Finally, we examined the ef-
fect of AP-3D-5# on the behavior of NL4-3 bearing a t
plarge deletion in MA, a construct previously shown to
bud predominantly into the endoplasmic reticulum n
iin Cos-7 cells (Facke et al., 1993). Expression of AP-D-5# did not block the intracellular budding of the MA-
eleted virus (Figure 7L), suggesting that this MA dele-
ion targets Gag to alternative intracellular membranes
y a pathway that does not involve the AP-3 complex.
iscussion
ur experiments demonstrate that HIV-1 Gag binds to
he δ subunit of the AP-3 complex. The extreme N ter-
inus of the MA region bound specifically to the hinge
egion of the δ subunit, and Gag constructs lacking MA
ailed to interact with AP-3. Particle formation by wild-
ype Gag was substantially diminished by a dominant-
egative AP-3δ fragment and by siRNA depletion of
P-3, indicating that the Gag-AP-3 interaction is part
f the normal productive trafficking pathway of Gag in
he cell. The trafficking of Gag to CD63-positive intra-
ellular compartments was effectively eliminated by the
isruption of the Gag-AP-3 interaction. Substitution of
he myristyl anchor from v-src for MA allowed efficient
article formation in the presence of the dominant-
egative inhibitor of the Gag-AP-3 interaction, suggest-
ng that this modification takes Gag to the plasma
AP-3 and HIV-1 Gag Trafficking
671membrane via a distinct pathway. These findings illumi-
nate a previously undescribed early step in the HIV as-
sembly pathway.
Adaptor Complexes and Intracellular Trafficking
Adaptor protein complexes are heterotetramers that
mediate the sorting of cargo proteins to specific mem-
brane compartments within the cell (Boehm and Boni-
facino, 2002; Nakatsu and Ohno, 2003; Robinson and
Bonifacino, 2001). Four adaptor protein complexes
have been described in mammalian cells, designated
AP-1 through AP-4. AP-3 was first identified through a
homology search of cDNA libraries together with data-
base searches (Dell’Angelica et al., 1997; Pevsner et al.,
1994; Simpson et al., 1996). Initial immunofluorescence
experiments localized AP-3 to the trans-Golgi network
and to more peripheral endosomal compartments (Dell’-
Angelica et al., 1997; Simpson et al., 1997). Cells that
are deficient in AP-3 demonstrate missorting of lyso-
somal membrane proteins, including lamp-1, lamp-2,
and CD63 (Dell’Angelica et al., 2000; Dell’Angelica et
al., 1999; Le Borgne et al., 1998; Rous et al., 2002). Ge-
netic deficiency of the AP-3 β3a subunit in humans
leads to a disorder termed Hermansky-Pudlak syn-
drome, in which defects in lysosome-related organelles
such as melanosomes and platelet dense granules are
apparent (Dell’Angelica et al., 2000; Starcevic et al.,
2002). AP-3 has been implicated in the movement of
lytic granules to the immunologic synapse (Clark et al.,
2003). A recent immuno-electron microscopy study
demonstrated that AP-3 localizes to a tubular sorting
endosome compartment (Peden et al., 2004).
We found that the N terminus of the MA region of Gag
interacts directly with the AP-3 δ subunit. A number of
previous findings make arguments for the biological rel-
evance of this Gag-AP-3 interaction compelling. The
MA region has been strongly implicated in the intracel-
lular trafficking of Gag (Facke et al., 1993; Ono and
Freed, 1999; Ono et al., 1997; Ono et al., 2000; Spear-
man et al., 1994). Recent observations by multiple
groups indicate that Gag traffics to late endosomes,
where Gag and CD63 are found to strongly colocalize
(Nguyen et al., 2003; Nydegger et al., 2003; Ono and
Freed, 2004; Sherer et al., 2003; von Schwedler et al.,
2003). AP-3 is involved in the trafficking of CD63 itself
through an interaction between the  subunit and the
lysosomal targeting motif GYEVM on the cytoplasmic
tail of CD63 (Dell’Angelica et al., 1999; Rous et al.,
2002). Thus Gag may traffic together with CD63 to late
endosomal compartments, explaining the previously
recognized high degree of colocalization of these two
molecules. Interaction with AP-3 thereby provides a
specific means by which Gag can reach the late endo-
some/MVB, where it may acquire components of the
ESCRT pathway that are essential to the normal HIV
budding process. In most cell types, Gag may then
move by other mechanisms from the MVB to the
plasma membrane. This model of Gag trafficking and
particle assembly predicts that essential components
of the particle budding machinery must be acquired in
the MVB, and this machinery is redirected to the
plasma membrane by Gag. In some cells, such as ma-
crophages, AP-3-mediated trafficking of Gag to theMVB is followed by viral budding into the lumen of the
MVB. The intact viral particles within the MVB or “viral
exosome” may be transported subsequently to the cell
surface for release.
It is important to recognize that alternative trafficking
models can be proposed to explain our data. One in-
triguing model states that Gag first reaches the tubular
recycling endosome in an AP-3-dependent manner.
From there, Gag may follow either a “default” recycling
pathway to reach the plasma membrane or continue on
an AP-3-dependent path to the MVB in a manner sim-
ilar to the trafficking of lysosomal membrane proteins
(Peden et al., 2004). Factors that regulate the choice of
one of these pathways may differ by cell type and may
be invoked to explain plasma membrane budding seen
in lymphocytes versus MVB budding in macrophages.
These models require direct testing in future experi-
ments. Recently a dileucine motif in the capsid region
of Gag has been identified as an interaction site for the
AP-2  subunit (Lindwasser and Resh, 2004). This motif
was functionally active in the context of a Gag-CD4
chimeric molecule, suggesting that it may act to bring
plasma membrane Gag into endocytic trafficking path-
ways. The potential involvement of multiple adaptor
family members in Gag trafficking thus may contribute
to the overall complexity of Gag trafficking in the cell.
Implications for Adaptor Protein Involvement
in Additional Steps in Virus Assembly
Our data demonstrating that productive HIV particle
formation utilizes the AP-3 trafficking pathway have
several potential implications for HIV particle assembly.
It is not yet known where Gag and Env meet within the
cell. The cytoplasmic tail of gp41 contains a tyrosine-
based signal that is active in promoting clathrin-medi-
ated endocytosis through an interaction with the  sub-
unit of AP-2 (Berlioz-Torrent et al., 1999; Boge et al.,
1998). It is possible that cell-surface Env complexes are
internalized to a sorting/recycling endosome compart-
ment, where they may become associated with Gag.
Notably, the 3A subunit is also capable of interacting
with the endocytosis motif in the gp41 cytoplasmic tail
(Ohno et al., 1997), raising the possibility that Gag and
Env may interact on the same adaptor protein complex.
Trafficking of both Gag and Env to the MVB through
AP-3 interactions would be consistent with the obser-
vation that Gag and Env both traffic to the MVB and
that infectious particles form within the MVB lumen of
macrophages (Pelchen-Matthews et al., 2003).
The identification of the δ subunit of AP-3 as a Gag
binding partner may also help to elucidate unique func-
tions of this subunit. To our knowledge, there are no
known cellular binding partners for the hinge region of
this subunit. In yeast, a component of the Vps pathway,
Vps41, binds to the carboxyl terminus of the δ subunit
homolog Apl5p and contributes to the transport of alka-
line phosphatase to the vacuole (Darsow et al., 2001;
Rehling et al., 1999). It will be important to identify δ
subunit binding partners in mammalian cells in order
to better understand the role played by this subunit in
vesicular trafficking. It is possible that Gag binds to a
site on the δ subunit that is also utilized by cellular
cargo proteins, in a manner analogous to that in which
Cell
672tGag competes with the Hrs protein for binding to cellu-
clar pools of TSG101.
lIn summary, Gag binds to the AP-3 complex and
a
uses this route to reach the MVB. This appears to be a p
productive pathway for HIV particle assembly, even in C
tcell types in which particle assembly takes place pre-
tdominantly on the plasma membrane. The identifica-
etion of the Gag-AP-3 interaction elucidates one piece
of an increasingly complex pathway by which viral and






pNL4-3 was obtained from Dr. Malcolm Martin through the NIH
i
AIDS Reference and Reagent Program. Expression constructs for
f
the AP-3 δ subunit (AP-3D) were derived from full-length cDNA
a
kindly provided by Margaret Robinson (University of Cambridge,
(
United Kingdom); AP-3 δ constructs including residues 1–742 (AP-
A
3D-5#) with or without an HA tag and 743–1203 (AP-3D-3#) were
W
generated by PCR cloning into pcDNA3.1. DNA encoding AP-3 δ
w
subunit residues 1–742 was also amplified and inserted into
A
pEYFP-C1 (Clontech) to generate YFP-AP-3D-5#. Full-length TSG101
t
was cloned from a HeLa cDNA library, and a 5# fragment (residues
10–240) was amplified and cloned into pCMV-HA (Clontech) to gen-
Rerate HA-TSG-5#. Codon-optimized Gag constructs were derived
Tfrom pVRC3900 provided by Gary Nabel (VRC, NIH) (Huang et al.,
o2001). Gag constructs with or without a carboxy-terminal myc epi-
rtope tag and with a deletion of the MA region (codons 1–132) fused
1to the N-terminal 9 residues of v-src were generated by PCR clon-
Ging into pCDNA3.1. Matrix deletion constructs (pMAD1-10) were
(provided by Max Essex (Harvard University, Boston, Massachu-
gsetts) (Yu et al., 1992) and were cloned into yeast 2-hybrid vector
kpGBKT7 for yeast expression (Clontech) using the Nde1 and
tBamH1 sites. A series of Gag protein truncation products were also
Acloned into pGBKT7 for directed yeast 2-hybrid assays. GST fusion
Gconstructs with specific regions derived from the codon-optimized
Igag gene were created (MA, CA, NC, p6, MACA, MACANC,
tCANCp6, full-length Gag) by PCR cloning into pGEX-2T (Amersham
FPharmacia), as was a GST fusion with the AP-3 binding domain
i(residues 554–844). All expression constructs were verified by se-
mquencing throughout the amplified regions. Expression vector Gag-
CFP has been previously described (Derdowski et al., 2004), and
Ithe construct 3-CCCC for Gag-Pol expression was a gift from
HHans-Georg Krausslich (University of Hamburg, Germany) (Wodrich
wet al., 2000). pNL4-3 bearing a large deletion in the MA coding re-
fgion (lacking codons 16 to 99) identical to a construct previously
pdescribed (Facke et al., 1993) was created by PCR mutagenesis.
PA stably transduced 293 cell line expressing Gag and Env from a
0tetracycline-inducible promoter was created using the RevTet vec-
Ctor system (Clontech). This cell line (293/Gag-Env) incorporates co-
wdon-optimized gag and env genes separated by an internal ribo-
gsome entry site under the control of the tetracycline-responsive
Gpromoter for coordinated, inducible expression of Gag and Env.
t
gYeast Two-Hybrid Assays
fTwo-hybrid library screening was performed using full-length co-
idon-optimized Gag (codons 1–1503) as bait fused to codons 1–147
fof the Gal4 DNA binding domain (BD) in vector pGBKT7 (Clontech).
wPrey constructs were derived from a human HeLa cDNA library
fused to the C terminus of codons 768–881 from the Gal4 activation
domain in vector pACT2, and yeast 2-hybrid screening performed E
Taccording to the manufacturer’s instructions (Clontech). For liquid
culture assays, cells in mid-log phase were processed as described w
e(Schneider et al., 1996) and β-galactosidase units were quantitated
in a spectrophotometer. 2
a
tProtein Expression and GST Pulldown
GST fusion proteins were expressed in E. coli BL21 (DE3) cells (No- b
tvagen) and purified using glutathione-sepharose beads. The immo-
bilized GST fusion proteins were incubated for 2–4 hr at 4°C with (
c293T cell lysates, washed extensively, and eluted, followed by de-ection by Western blotting using the monoclonal antibodies indi-
ated below. The interaction region fragment was produced simi-
arly as a GST fusion and then exposed to ρ-amino-benzamidine-
garose beads for removal of thrombin. The interaction domain
rotein was then dialyzed against PBS in a Slide-A-Lyzer Dialysis
assette (Pierce). For interaction experiments, 30 l of a concen-
rated preparation was added to each of the Gag-GST fusion pro-
eins, and an equal amount analyzed on the gel used to detect the
luted proteins by Coomassie staining.
ntibodies and Coimmunoprecipitation
93T cells were maintained in Dulbecco’s modified Eagle medium
ith 10% fetal bovine serum and antibiotics at 37°C in 5% CO2 and
rown in 10 cm2 culture dishes. Transfections were performed by
he calcium phosphate method. Cells were harvested 36–48 hr
osttransfection, washed, and broken by dounce homogenization
n hypotonic buffer. The cell lysates were centrifuged at 1500 × g
or 10 min, and the supernatants were immunoprecipitated with
nti-HA, anti-Myc, or anti-p24 monoclonal antibody 183-H12-5C
provided by Bruce Chesebro and Kathy Wehrly through the NIH
IDS Research and Reference Reagent Program) then detected by
estern blotting. Antibodies used for detection of AP subunits
ere from BD Biosciences 611328 for AP-3 δ subunit, 610900 for
P-3  subunit, and 610385 for AP-1 γ subunit; antibody for ca-
hepsin D was sc-6486 (Santa Cruz).
NA Interference (RNAi)
wenty-one nucleotide siRNA duplexes with symmetric two nucle-
tide 3#-UU overhangs were obtained from Dharmacon and cor-
espond to the following AP-3 δ subunit targets: nucleotides 176–
94 (TCTGCAAGCTGACGTATTT), 489–507 (GAAGAAGGCTGTGCT
ATC), 2438–2456 (GCGAGAAACTGCCTATTCA), and 2493–2511
GAAGGACGTTCCCATGGTA). An additional siRNA reagent was
enerated in our laboratory using the Silencer siRNA construction
it (Ambion) following the manufacturer’s instructions and targeting
he AP-3  subunit nucleotides 237–255 (TTGAGTTCCTACATCG
GT). Control siRNA duplexes were duplex I sense strand (GCUGA
UAUACGCGGAUGUUU) with 53% GC content and control duplex
I (ACCACCAACAUAUCUACGCUU) with 47% GC content. siRNA
ransfection was performed with Lipofectamine 2000 (Invitrogen).
or each siRNA knockdown experiment, 100 nM siRNA was used
n experimental and control arms, and the control siRNA used was
atched for GC content to the active arm.
mmunofluorescence Microscopy
eLa cells were grown on glass cover slips in 6-well plates and
ere transfected using with Lipofectamine 2000 (Invitrogen). Trans-
ected cells were fixed with 3.8% formaldehyde in sodium phos-
hate buffer, stabilized in cytoskeletal stabilization buffer (100 mM
IPES, 1 mM EDTA, 3% PEG6000, pH 6.9), permeabilized with
.1% Triton X-100, and blocked with 5% bovine serum albumin.
ells were incubated with mouse anti-Lamp-3 (1:100, Santa Cruz),
ashed, and incubated with goat anti-mouse Alexa 546-conju-
ated antibodies (1:3000, Molecular Probes). In some experiments,
ag staining was performed with polyclonal anti-p17 antisera (Var-
hakavi et al., 2002) detected via goat anti-rabbit Alexa 546-conju-
ated antibodies, and CD63 was revealed by mouse anti-Lamp-3
ollowed by anti-mouse Alexa 633-conjugated antibodies. Confocal
mages were acquired using a Zeiss LSM510 laser-scanning con-
ocal microscope (Carl Zeiss Inc.), and data analysis performed
ith MetaMorph software (Universal Imaging Corporation).
lectron Microscopy
ransfected 293T cells or doxycycline-induced 293/Gag-Env cells
ere fixed, sectioned, and stained in preparation for transmission
lectron microscopy as previously described (Sandefur et al.,
000). Post-embedding immunogold labeling of samples for CD63
nd Gag was performed using LR white-embedded 100 nm sec-
ions essentially as previously described (Wang et al., 2001). Anti-
odies for these studies included polyclonal anti-p17 antisera (Var-
hakavi et al., 2002) and anti-LAMP3 murine monoclonal antibody
sc-5275, Santa Cruz Biotechnology). Fifteen nanomolar gold beads
onjugated to goat anti-mouse IgG antibody and 6 nm gold beads
AP-3 and HIV-1 Gag Trafficking
673conjugated to goat anti-rabbit IgG were purchased from EM Sci-
ences. Images were obtained on a Philips CM-12 electron micro-
scope equipped with a high-resolution CCD camera.
Supplemental Data
Supplemental Data include two figures and can be found with this
article online at http://www.cell.com/cgi/content/full/120/5/663/
DC1/.
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